Abstract 33P
Background
To investigate the feasibility of virtual monoenergetic images (VMIs) derived from a dual-layer detector spectral CT (SDCT) in patients with breast cancer by assessing tumor conspicuity in comparison with conventional images (CI) and to correlate tumor conspicuity on VMIS with prognostic biomarkers.
Methods
64 patients with pathologically proven benign or breast cancers (14 benign lesions and 65 breast cancers) underwent arterial and 90s delayed phase scan on a SDCT for tumor staging between June 2016 and May 2018. CI were reconstructed at 120kVp, and VMI at 40 keV (VMI40). A retrospective spectral data analysis was performed to assess the regions of interest by using CI and VMI40 on arterial and delayed images (CIART, VMI40ART, CIDE, and VMI40DE). Two radiologists independently reviewed the 4 image sets for the conspicuity score of breast lesions. For quantitative analysis, measurement of Hounsfield units (HU) of breast lesions on VMI40ART and VMI40DE was performed. Receiver operating characteristic (ROC) analysis was performed. Estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), and Ki67 level were evaluated using histopathology. Statistically, conspicuity score and mean HU of malignant lesions were correlated with histological characteristics.
Results
The mean conspicuity score of malignant lesions was significantly higher compared with that of benign lesions in all image sets (P < 0.05). The area under the ROC curve of conspicuity score for malignant lesions were greatest on VMI40DE. VMI40DE yielded significantly higher mean HU of malignant lesions compared to VMI40ART (P < 0.001). Malignant lesions on VMI40ART and VMI40DE revealed significantly higher mean HU compared to those of benign lesions (P < 0.001). The conspicuity score and the mean HU on VMI40ART were significantly higher in cancers with diameter greater than 2 cm, ER negativity, PR negativity, and Ki67 positivity (P < 0.05).
Conclusions
VMI40DE is feasible to diagnose breast cancers with higher conspicuity score and better contrast enhancement compared with VMI40ART. Moreover, VMI40ART may serve as additional predictors of a poor breast cancer prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
381P - XKR8 is a promising potential prognostic marker in glioblastoma multiforme patients
Presenter: Kristina Havrysh
Session: Poster display session
Resources:
Abstract
383P - Screening of prognostic molecular biomarker for resectable pancreatic cancer
Presenter: Yonggang Peng
Session: Poster display session
Resources:
Abstract
384P - Prevalence of abnormal microsatellite instability test among ovary and endometrial cancer patients
Presenter: Min Kyu Kim
Session: Poster display session
Resources:
Abstract
385P - Identifying CASP8 polymorphisms associated with breast cancer risk in an Iranian population
Presenter: Alireza Pasdar
Session: Poster display session
Resources:
Abstract
386P - Unusual folding of NaPi2b transporter extramembrane domain 4 during malignant transformation
Presenter: Leysan Minigulova
Session: Poster display session
Resources:
Abstract
387P - 5-years conditional disease free survival and overall survival for breast cancer patients in South Korea
Presenter: Jee hyun Ahn
Session: Poster display session
Resources:
Abstract
388P - To identify circulating tumour cells by machine learning approach
Presenter: Yuebin Liang
Session: Poster display session
Resources:
Abstract
389P - The establishment of patient-derived organoid models and drug response of resectable non-small cell lung cancer
Presenter: Jing-Hua Chen
Session: Poster display session
Resources:
Abstract
395P - Filipinos and lung cancer: An infodemiological assessment using Google trends from 2009 to 2019
Presenter: Lance Isidore Catedral
Session: Poster display session
Resources:
Abstract
396P - Determinants of visiting a referral hospital for cervical cancer screening at Uganda Cancer Institute
Presenter: Collins Mpamani
Session: Poster display session
Resources:
Abstract